Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL)
Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL). // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026040243?dgcid=rss_sd_all
Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL). Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026040243?dgcid=rss_sd_all
“Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL).” Clinical Lymphoma, Myeloma & Leukemia.
@article{article40970,
title = {Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL)},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026040243?dgcid=rss_sd_all}
}